| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | July 30, 2026 | 6/12 | 1 high, 3 medium, 2 low flags | 3 | 2 | Call sheet → |
| Q1'26 | April 30, 2026 | 7/12 | 2 medium, 3 low flags | 2 | 0 | Call sheet → |
| Q4'25 | February 5, 2026 | 8/12 | 2 medium, 4 low flags | 5 | 1 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Delivered | Continue disciplined capital allocation Paid down $1.2B debt, maintained dividend |
| Q2'26 | Exceeded | Eliquis tracking toward upper end of guidance Raised to 20-25% growth from prior expectations |
| Q2'26 | Pending | Phase 3 non-obstructive HCM study for Camzios Said will initiate by year-end, timeline intact |
| Q2'26 | Delivered | Growth portfolio continuing momentum 14% growth exceeding the 9% from Q1 |
| Q2'26 | Missed | ADEPT readouts by end of 2026 Delayed to early 2027 citing enrollment quality and slower relapse rates |
| Q2'26 | Missed | Milvexian AFib readout by end of 2026 Pushed to Q1 2027 due to slower event rates |
| Q1'26 | Pending | Growth portfolio offsetting legacy portfolio declines Q1 showed growth portfolio up 9% but legacy down impact still material |
| Q1'26 | Delivered | $1B cost savings in 2025 Confirmed delivered, remainder spread over 2026-2027 |
| Q1'26 | Pending | Cobenfy steady growth throughout 2026 Q1 growth maintained but not accelerated |
| Q1'26 | Pending | Six pivotal readouts by end of 2026 Still expecting Milvexian AFib/SSP, Admilparant IPF, iberdomide PFS, mezigdomide, Arlocell |
| Q1'26 | Delivered | Eliquis growth 10-15% in 2026 Q1 showed 13% growth, within promised range |
| Q1'26 | Pending | Track towards upper end of 2026 guidance ranges Reaffirmed 2026 guidance, said tracking to upper end based on Q1 |
| Q4'25 | Exceeded | $10B debt paydown by H1 2026 Completed ahead of schedule in 2025 |
| Q4'25 | Pending | Pipeline data acceleration in 2026 Six readouts confirmed but pushed to H2, creates concentration risk |
| Q4'25 | Delivered | Breyanzi continuing strong performance 47% Q4 growth and crossed $1B annualized |
| Q4'25 | Delivered | Eliquis continued growth through Part D changes 6% Q4 growth delivered with 10-15% guided for 2026 |
| Q4'25 | Delivered | Growth portfolio continuing momentum 15% Q4 growth delivered, though slower than Q3's 17% |
| Q4'25 | Delivered | $1 billion cost savings in 2025 Achieved target savings as committed |
| Q4'25 | Missed | ADEPT-2 results by end of Q4 2025 Study clearly did not report in Q4 2025 despite repeated commitments, major execution miss |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.